National Distributor Eager To Begin Sales & Marketing Of Vascular Compression Therapy Solutions

Toronto, Ontario--(Newsfile Corp. - January 21, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that it has secured a purchase order for 1,750 Venowave VW5 from national distribution partner DME Authority of Nashville, Tennessee. DME, along with their partner network, was just one of the Company's national distributors who have experienced successful pilot trials.

Last month, distribution partner DME Authority signed a Letter of Intent (LOI) for distributing the Venowave VW5 to its U.S. distribution network. This purchase order brings both companies one step closer to the outlined LOI that positions DME as a 'Premier Distributor Partner' for Therma Bright. This initial purchase order for 1750 Venowave VW5 units offers HCPCS code reimbursements that total $1,434,212 USD, which equates to $2,051,602 CAD.

"It is very exciting to see our distribution program with DME come to fruition," shared Rob Fia, CEO of Therma Bright. "Our current inventory is seeing great traction, so we've begun the process with our new manufacturing partner to begin production on new inventory, which we anticipate will arrive to meet the demand of our growing national distribution network. As always, we will keep the market updated on our progress with sales and manufacturing."

The global compression therapy market was valued at $4.18 billion in 2024 and is projected to grow to $6.72 billion by 2033. This represents a compound annual growth rate (CAGR) of 7.30% from 2025 to 2033," per a Straits Research press announcement in November 2024.

About Venowave VW5
The Venowave VW5 is a compact, battery-operated peristaltic pump designed to diminish post-op pain & swelling and enhance blood circulation while harnessing the multitude of advantages that come with increased venous blood flow by 64% after 2 minutes of use, and 88% increased blood flow after 50 minutes of use. When positioned below the knee, the device generates a wave-form motion that promotes fluid displacement, improving circulation and lymphatic function. The FDA-designated Durable Medical Equipment (DME) device is currently the only Medicare approved reimbursable mobile mechanical compression system available in the US under its HCPCS code E0683, which provides a simple and comfortable mobile treatment solution for patients needing to accelerate post-operative recovery periods while also managing longer term pain and swelling issues.

About DME Authority, LLC
DME Authority partners with a select network of top-tier medical distributors and healthcare providers to deliver outcome-driven solutions that set new standards for patient care. By aligning with forward-thinking organizations, we bring innovative sales and distribution strategies to life, backed by comprehensive billing expertise and strategic funding programs. Our unique approach ensures our partners achieve unmatched success while transforming healthcare delivery across the U.S. Visit: www.dmeauthority.com

About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.

FORWARD-LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237912